_
Entresto is associated with reverse cardiac remodelling and improvement in cardiac function1,2
Dr James Januzzi, Principal Investigator of PROVE-HF, summarises the PROVE-HF study and gives a real-world example of a patient in his clinic.
Read the EVALUATE-HF study paper
There’s a wealth of data supporting the use of Entresto in your chronic HFrEF patients1–7
Paradigm-hf3 Pioneer-hf4 Transition5,6 Prove-hf1 Evaluate-hf2
Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.7
HFrEF, heart failure with reduced ejection fraction.
References
- Januzzi JL Jr et al. JAMA 2019; 322:1085–1095.
- Desai AS et al. JAMA 2019; 322:1077–1084.
- McMurray JJV et al. N Engl J Med 2014; 371:993–1004.
- Velazquez EJ et al. N Engl J Med 2019; 380:539–548.
- Wachter R et al. Eur J Heart Fail 2019; 21:998–1007.
- Pascual-Figal D et al. ESC Heart Fail 2018; 5:327–336.
- Entresto Summary of Product Characteristics, 2020.
Rate this content:
ENT20-C046e(1) July 2020.